CLIN CHEM LAB MED: High-efficiency liquid chromatography-series mass spectrometry to simultaneously determine hydroxychloroquine and its metabolites in the entire blood of a person?

Hydroxychloroquine (HCQ) is an antimalarial and immunomodulation drug that is reported to inhibit the coronavirus SARS-CoV-2 in-body.
, there is not enough clinical trial evidence to determine the safety and effectiveness of HCQ as COVID-19.
However, since the World Health Organization declared COVID-19 a pandemic in March 2020, the U.S. Food and Drug Administration has issued emergency use authorizations to allow the distribution of HCQ and chloroquine (CQ) to certain hospitalized COVID-19 and many clinical trials are under way around the world, including the UK RECOVERY trial involving more than 1,000 volunteers.
this study describes the effectiveness of liquid chromatography series mass spectrometry (LC-MS/MS) for simultaneous determination of HCQ and its two main metabolites, deethyl chloroquine (DCQ) and DDDCQ.
blood samples were deproteinated with acetylene.
HCQ, DCQ, and DDCQ are separated by gradient-de-ion column chromatography at a flow rate of 500 flow L/min.
analysis time is 8 minutes.
the linear calibration curve of each ads obtained in the concentration range of 50-2000 μg/L, the quantitative lower limit (LLOQ) is 13 μg/L, and the relative standard deviation between measurements at 25 °C (RSD) 10%, HCQ, d4-HCQ, DCQ and DCQ, respectively, 800 and 1750 μg/L, with an average recovery rate of 80%, 81%, 78% and 62%, respectively.
results show that the method has good analytical performance, is suitable for therapeutic monitoring of HCQ, evaluates the pharmacological dynamics of HCQ in COVID-19 patients, and supports clinical trials.
。